Adamas Pharmaceuticals Inc Contracts & Agreements
75 Contracts & Agreements
- Business Finance (21 contracts)
- Business Operations (3)
- Human Resources (24)
- Intellectual Property (2)
- Mergers & Acquisitions (1)
- Real Estate (9)
- Uncategorized (15)
- Agreement and Plan of Merger, dated as of October 10, 2021, by and among Supernus, Supernus Reef, Inc. and Adamas Pharmaceuticals, Inc (Filed With SEC on October 12, 2021)
- First Amendment to Asset Purchase Agreement by and between Adamas Pharmaceuticals, Inc. and Osmotica Pharmaceutical US LLC (Filed With SEC on August 9, 2021)
- Binding Term Sheet by and between Adamas Pharma, LLC and Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc (Filed With SEC on May 10, 2021)
- Form of Performance Restricted Stock Unit Grant Notice and Award Agreement (Filed With SEC on May 10, 2021)
- Underwriting Agreement, dated February 24, 2021, by and between the Company and SVB Leerink LLC and William Blair & Company, L.L.C., as representatives of the underwriters named... (Filed With SEC on February 25, 2021)
- Asset Purchase Agreement by and between Adamas Pharmaceuticals, Inc. and Osmotica Pharmaceutical US LLC (Filed With SEC on February 23, 2021)
- Adamas Pharmaceuticals, Inc. Amended and Restated 2016 Inducement Plan (Filed With SEC on February 23, 2021)
- Adamas Pharmaceuticals, Inc. Amended and Restated Executive Severance Plan (Filed With SEC on February 23, 2021)
- Compensation arrangements with Executive Officers (Filed With SEC on February 23, 2021)
- Amendment No. 3 to the Loan Agreement dated December 1, 2020 between Adamas Pharma, LLC and Healthcare Royalty Partners III, L.P (Filed With SEC on February 23, 2021)
- Extension to Separation and consulting agreement by and between Adamas Pharmaceuticals, Inc. and Rajiv Patni, dated July 15, 2020 (Filed With SEC on November 5, 2020)
- Adamas Pharmaceuticals, Inc. Amended and Restated 2016 Inducement Plan (Filed With SEC on November 5, 2020)
- Separation and consulting agreement by and between Adamas Pharmaceuticals, Inc. and Jennifer Rhodes, dated January 9, 2020 (Filed With SEC on May 7, 2020)
- Separation and consulting agreement by and between Adamas Pharmaceuticals, Inc. and Rajiv Patni, dated February 25, 2020 (Filed With SEC on May 7, 2020)
- 2020 Compensation actions with respect to Non-Employee Directors (Filed With SEC on May 7, 2020)
- Description of Capital Stock (Filed With SEC on February 25, 2020)
- Adamas Pharmaceuticals, Inc. Amended and Restated 2016 Inducement Plan (Filed With SEC on February 25, 2020)
- Amendment No. 2 to the Loan Agreement dated January 2, 2020 between Adamas Pharma, LLC and Healthcare Royalty Partners III, L.P (Filed With SEC on February 25, 2020)
- Binding Term Sheet by and between Adamas Pharma, LLC and Sandoz, Inc (Filed With SEC on February 25, 2020)
- Separation and consulting agreement by and between Adamas Pharmaceuticals, Inc. and Alfred G. Merriweather, dated August 7, 2019 (Filed With SEC on November 7, 2019)
- Transition, separation, and consulting agreement by and between Adamas Pharmaceuticals, Inc. and Gregory T. Went, Ph.D., dated September 11, 2019 (Filed With SEC on November 7, 2019)
- Employment Offer by and between Adamas Pharmaceuticals, Inc. and Neil F. McFarlane, dated September 12, 2019 (Filed With SEC on November 7, 2019)
- Offer Letter by and between Adamas Pharmaceuticals, Inc. and Vijay Shreedhar, Ph.D., dated May 14, 2019 (Filed With SEC on August 8, 2019)
- First Amendment to Amended and Restated Commercial Supply Agreement by and between Adamas Pharmaceuticals, Inc. and Catalent Pharma Solutions, LLC (Filed With SEC on August 8, 2019)
- Adamas Pharmaceuticals, Inc. Amended and Restated 2016 Inducement Plan (Filed With SEC on March 4, 2019)
- Eighth Amendment to Lease by and between the registrant and KBSIII Towers At Emeryville, LLC, dated as of August 2, 2018 (Filed With SEC on November 1, 2018)
- Separation and consulting agreement by and between the registrant and Richard A. King, dated September 13, 2018 (Filed With SEC on November 1, 2018)
- 2018 compensation actions with respect to Non-Employee Directors (Filed With SEC on August 2, 2018)
- Secured Promissory Note dated November 27, 2017 between Adamas Pharma, LLC and Healthcare Royalty Partners III, L.P (Filed With SEC on February 22, 2018)
- Seventh Amendment to Lease by and between the registrant and KBSIII Towers At Emeryville, LLC, dated as of January 16, 2018 (Filed With SEC on February 22, 2018)
- Underwriting Agreement, dated January 23, 2018, by and among the Company and Merrill Lynch, Pierce, Fenner & Smith Incorporated, Leerink Partners LLC, and Evercore Group L.L.C.,... (Filed With SEC on January 24, 2018)
- Amended and Restated Commercial Supply Agreement by and between Adamas Pharmaceuticals, Inc. and Catalent Pharma Solutions, LLC (Filed With SEC on November 2, 2017)
- Amended and Restated API Supply Agreement by and between Adamas Pharma, LLC and Moehs Ibrica, S.L (Filed With SEC on November 2, 2017)
- Offer Letter by and between the registrant and Richard A. King, dated April 17, 2017 (Filed With SEC on August 8, 2017)
- Offer Letter by and between the registrant and Alfred G. Merriweather, dated June 26, 2017 (Filed With SEC on August 8, 2017)
- Separation Agreement by and between the registrant and William Dawson, dated June 27, 2017 (Filed With SEC on August 8, 2017)
- Loan Agreement dated May 11, 2017 between Adamas Pharma, LLC and Healthcare Royalty Partners III, L.P (Filed With SEC on August 8, 2017)
- Secured Promissory Note dated May 11, 2017 between Adamas Pharma, LLC and Healthcare Royalty Partners III, L.P (Filed With SEC on August 8, 2017)
- ADAMAS PHARMACEUTICALS, INC. $50,000,000 COMMON STOCK SALES AGREEMENT (Filed With SEC on May 11, 2017)
- Amended and Restated Adamas Pharmaceuticals, Inc. Executive Severance Plan (Filed With SEC on May 9, 2017)
- 2017 Executive Cash Bonus Award Program (Filed With SEC on April 5, 2017)
- AnnualAnnualChairMemberCommitteeFeeFeeAudit Committee$15,000 $7,500 Compensation Committee$10,000 $5,000 Nominating and Corporate Governance Committee$7,000 $3,500 Development... (Filed With SEC on February 28, 2017)
- CONSULTING SERVICES AGREEMENT (Filed With SEC on November 3, 2016)
- 1900 Powell St. Suite 750 Emeryville, CA 94608 Tel ###-###-#### Fax ###-###-#### www.adamaspharma.com (Filed With SEC on May 10, 2016)
- 2016 Executive Cash Bonus Award Program (Filed With SEC on May 10, 2016)
- SIXTH AMENDMENT TO LEASE (Filed With SEC on February 23, 2016)
- ADAMAS PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on February 23, 2016)
- 2,500,000 Shares ADAMAS PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on January 7, 2016)
- 1900 Powell St. Suite 750 Emeryville, CA 94608 Tel ###-###-#### Fax ###-###-#### www.adamaspharma.com (Filed With SEC on August 11, 2015)
- ADAMAS PHARMACEUTICALS INC. 2014 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE (Filed With SEC on August 11, 2015)
- 2200 Powell St. Suite 220 Emeryville, CA 94608 Tel ###-###-#### Fax ###-###-#### www.adamaspharma.com (Filed With SEC on May 13, 2015)
- 2200 Powell St. Suite 220 Emeryville, CA 94608 Tel ###-###-#### Fax ###-###-#### www.adamaspharma.com (Filed With SEC on August 13, 2014)
- EXHIBIT A Confidential Information and Invention Assignment Agreement (Filed With SEC on August 13, 2014)
- FIFTH AMENDMENT TO LEASE (Filed With SEC on August 7, 2014)
- ADAMAS PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 20, 2014 APPROVED BY THE STOCKHOLDERS: MARCH 23, 2014 IPO DATE/EFFECTIVE DATE:... (Filed With SEC on April 7, 2014)
- LICENSE AGREEMENT BY AND BETWEEN FOREST LABORATORIES HOLDINGS LIMITED AND ADAMAS PHARMACEUTICALS, INC. DATED AS OF NOVEMBER 13, 2012 (Filed With SEC on April 7, 2014)
- ADAMAS PHARMACEUTICALS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 20, 2014 APPROVED BY THE STOCKHOLDERS: MARCH 23, 2014 (Filed With SEC on March 26, 2014)
- [] Shares Adamas Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on March 20, 2014)
- NEUROMOLECULAR, INC. 2002 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN (Filed With SEC on March 5, 2014)
- ADAMAS PHARMACEUTICALS, INC. 2007 STOCK PLAN ADOPTED ON DECEMBER 12, 2007 AMENDED THROUGH SEPTEMBER 3, 2013 (Filed With SEC on March 5, 2014)
- ADAMAS PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 20, 2014 APPROVED BY THE STOCKHOLDERS: , 2014 IPO DATE/EFFECTIVE DATE: , 2014 (Filed With SEC on March 5, 2014)
- ADAMAS PHARMACEUTICALS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 20, 2014 APPROVED BY THE STOCKHOLDERS: , 2014 (Filed With SEC on March 5, 2014)
- ADAMAS PHARMACEUTICALS, INC. FOURTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT June 30, 2011 (Filed With SEC on March 5, 2014)
- LICENSE AGREEMENT BY AND BETWEEN FOREST LABORATORIES HOLDINGS LIMITED AND ADAMAS PHARMACEUTICALS, INC. DATED AS OF NOVEMBER 13, 2012 (Filed With SEC on March 5, 2014)
- WATERGATE OFFICE TOWERS EMERYVILLE TOWER 1 EMERYVILLE, CALIFORNIA OFFICE LEASE AGREEMENT BETWEEN CA-EMERYVILLE PROPERTIES LIMITED PARTNERSHIP, a Delaware limited partnership... (Filed With SEC on March 5, 2014)
- FIRST AMENDMENT TO LEASE (Filed With SEC on March 5, 2014)
- SECOND AMENDMENT TO OFFICE LEASE AGREEMENT (Filed With SEC on March 5, 2014)
- THIRD AMENDMENT TO LEASE (Filed With SEC on March 5, 2014)
- FOURTH AMENDMENT TO LEASE (Filed With SEC on March 5, 2014)
- 1900 Powell St., Suite 210 Emeryville, CA 94608 Office: 510 ###-###-#### Fax ###-###-#### (Filed With SEC on March 5, 2014)
- 2200 Powell St. Suite 220 Everyville, CA 94608 Tel | 510 ###-###-#### Fax | 510 ###-###-#### www.adamaspharma.com (Filed With SEC on March 5, 2014)
- 2200 Powell St. Suite 220 Emeryville, CA 94608 Tel ###-###-#### Fax ###-###-#### www.adamaspharma.com (Filed With SEC on March 5, 2014)
- ADAMAS PHARMACEUTICALS, INC. INDEMNITY AGREEMENT (Filed With SEC on March 5, 2014)
- ADAMAS PHARMACEUTICALS, INC. TRANSACTION BONUS PLAN (Filed With SEC on March 5, 2014)
- Adamas Pharmaceuticals, Inc. Executive Severance Plan (Filed With SEC on March 5, 2014)